Abstract
Background
Several studies have reported survival benefits of combination therapy with intraarterial 5-fluorouracil (5-FU) and subcutaneous interferon (IFN) α for advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). We investigated the pretreatment predictive factors of early response, time to progression (TTP), and survival in response to intraarterial 5-FU/IFN combination therapy.
Methods
Patients with nonresectable HCC and variable PVTT grades (without PVTT to PVTT in the trunk) received intraarterial 5-FU/IFN combination therapy (n = 55).
Results
After two courses of the combination therapy, 1 (2%), 15 (27%), 16 (29%), 12 (22%), and 11 (20%) of 55 patients showed complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), or had dropped out (DO), respectively, when their early response to treatment was assessed. Univariate analysis identified only hepatitis C virus (HCV) antibody positivity as having significantly influenced the early response (P = 0.028) and TTP (P = 0.021). Multivariate analysis identified performance status (P = 0.003) and HCV antibody positivity (P = 0.007) as significant and independent determinants of survival. PVTT grade did not influence early response, TTP, or survival. The survival rate was significantly higher in patients who achieved CR or PR than in those that assessed as SD or PD, or DO (P < 0.0001, each).
Conclusions
HCV antibody positivity may be a significant pretreatment predictor of early response, TTP, and survival of patients with advanced HCC treated with 5-FU/IFN. CR or PR as the early response to the combination therapy might indicate a more favorable prognosis in patients with advanced HCC. PVTT grade did not seem to influence the efficacy of combination therapy.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
M Kobayashi K Ikeda T Hosaka H Sezaki T Someya N Akuta et al. (2006) ArticleTitleNatural history of compensated cirrhosis in the Child-Pugh class A compared between 490 patients with hepatitis C and 167 with B virus infections J Med Virol 78 459–65 Occurrence Handle16482557 Occurrence Handle10.1002/jmv.20562
K Okuda I Fujimoto A Hanai Y Urano (1987) ArticleTitleChanging incidence of hepatocellular carcinoma in Japan Cancer Res 47 4967–72 Occurrence Handle3040235 Occurrence Handle1:STN:280:BiiA3c7ktlc%3D
InstitutionalAuthorNameHealth and Welfare Statistics Association (2000) ArticleTitleHealth and welfare statistics J Health Welfare Stat 47 421
InstitutionalAuthorNameCancer of the Liver Italian Program (CLIP) investigators (1998) ArticleTitleA new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients Hepatology 28 751–5 Occurrence Handle10.1002/hep.510280322
JM Llovet J Bustamante A Castells R Vilana C Ayuso Mdel M Sala et al. (1999) ArticleTitleNatural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials Hepatology 29 62–7 Occurrence Handle9862851 Occurrence Handle10.1002/hep.510290145 Occurrence Handle1:STN:280:DyaK1M%2FotFKrsw%3D%3D
K Uka H Aikata S Takaki H Shirakawa SC Jeong K Yamashina et al. (2007) ArticleTitleClinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma World J Gastroenterol 13 414–20 Occurrence Handle17230611
K Kamada M Kitamoto H Aikata Y Kawakami H Kono M Imamura et al. (2002) ArticleTitleCombination of transcatheter arterial chemoembolization using cisplatin-lipiodol suspension and percutaneous ethanol injection for treatment of advanced small hepatocellular carcinoma Am J Surg 184 284–90 Occurrence Handle12354601 Occurrence Handle10.1016/S0002-9610(02)00933-9 Occurrence Handle1:CAS:528:DC%2BD38Xnt1Giu7o%3D
M Friedman (1983) ArticleTitlePrimary hepatocellular cancer-present results and future prospects Int J Radiat Oncol Biol Phys 9 1841–50 Occurrence Handle6319339 Occurrence Handle1:STN:280:BiuC3M7htlU%3D
JS Stehlin SuffixJr PD de Ipolyi PJ Greeff CJ McGaff SuffixJr BR Davis L McNary (1988) ArticleTitleTreatment of cancer of the liver. Twenty years' experience with infusion and resection in 414 patients Ann Surg 208 23–35 Occurrence Handle2839123 Occurrence Handle10.1097/00000658-198807000-00004
R Doci P Bignami F Bozzetti G Bonfanti R Audisio M Colombo et al. (1988) ArticleTitleIntrahepatic chemotherapy for unresectable hepatocellular carcinoma Cancer 61 1983–7 Occurrence Handle2834036 Occurrence Handle10.1002/1097-0142(19880515)61:10<1983::AID-CNCR2820611009>3.0.CO;2-V Occurrence Handle1:STN:280:BieC1MvisFQ%3D
E Ando F Yamashita M Tanaka K Tanikawa (1997) ArticleTitleA novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein Cancer 79 1890–6 Occurrence Handle9149014 Occurrence Handle10.1002/(SICI)1097-0142(19970515)79:10<1890::AID-CNCR8>3.0.CO;2-K Occurrence Handle1:CAS:528:DyaK2sXjtlerurc%3D
E Ando M Tanaka F Yamashita R Kuromatsu S Yutani K Fukumori et al. (2002) ArticleTitleHepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases Cancer 95 588–95 Occurrence Handle12209752 Occurrence Handle10.1002/cncr.10694
YC Lai CY Shih CM Jeng SS Yang JT Hu YC Sung et al. (2003) ArticleTitleHepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis World J Gastroenterol 9 2666–70 Occurrence Handle14669309 Occurrence Handle1:CAS:528:DC%2BD2cXmt1Cmtw%3D%3D
T Urabe S Kaneko E Matsushita M Unoura K Kobayashi (1998) ArticleTitleClinical pilot study of intrahepatic arterial chemotherapy with methotrexate, 5-fluorouracil, cisplatin, and subcutaneous interferon-alpha-2b for patients with locally advanced hepatocellular carcinoma Oncology 55 39–47 Occurrence Handle9428374 Occurrence Handle10.1159/000011833 Occurrence Handle1:CAS:528:DyaK1cXovVyg
M Sakon H Nagano K Dono S Nakamori K Umeshita A Yamada et al. (2002) ArticleTitleCombined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches Cancer 94 435–42 Occurrence Handle11900229 Occurrence Handle10.1002/cncr.10246 Occurrence Handle1:CAS:528:DC%2BD38XhtV2qs70%3D
H Ota H Nagano M Sakon H Eguchi M Kondo T Yamamoto et al. (2005) ArticleTitleTreatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-α and intra-arterial 5-fluorouracil: role of type I interferon receptor expression Br J Cancer 93 557–64 Occurrence Handle16106266 Occurrence Handle10.1038/sj.bjc.6602742 Occurrence Handle1:CAS:528:DC%2BD2MXpsFalurg%3D
S Obi H Yoshida R Toune T Unuma M Kanda S Sato et al. (2006) ArticleTitleCombination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion Cancer 106 1990–7 Occurrence Handle16565970 Occurrence Handle10.1002/cncr.21832 Occurrence Handle1:CAS:528:DC%2BD28XkvFGhs7s%3D
InstitutionalAuthorNameLiver Cancer Study Group of Japan (2000) The general rules for the clinical and pathological study of primary liver cancer (in Japanese) EditionNumber4th ed Kanehara Tokyo 19
MM Oken RH Creech DC Tormey J Horton TE Davis ET McFadden et al. (1982) ArticleTitleToxicity and response criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol 5 649–55 Occurrence Handle7165009 Occurrence Handle10.1097/00000421-198212000-00014 Occurrence Handle1:STN:280:BiyC2cbntlU%3D
Uka K, Aikata H, Takaki S, Miki D, Jeong SC, Hiramatsu A, et al. Similar effects of recombinant IFN alpha-2b and natural IFN alpha when combined with intraarterial 5-fluorouracil for the treatment of advanced HCC. Liver Int (in press)
P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein et al. (2000) ArticleTitleNew guidelines to evaluate the response to treatment in solid tumors (RECIST) guidelines J Natl Cancer Inst 92 205–16 Occurrence Handle10655437 Occurrence Handle10.1093/jnci/92.3.205 Occurrence Handle1:STN:280:DC%2BD3c7it1Gitg%3D%3D
NCI Common Toxicity Criteria. http://ctep.cancer.gov/reporting/ctc.html
HS Lee JS Kim IJ Choi JW Chung JH Park CY Kim (1997) ArticleTitleThe safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction: a prospective controlled study Cancer 79 2087–94 Occurrence Handle9179054 Occurrence Handle10.1002/(SICI)1097-0142(19970601)79:11<2087::AID-CNCR5>3.0.CO;2-M Occurrence Handle1:STN:280:ByiA383ls1A%3D
W Ohishi M Kitamoto H Aikata K Kamada Y Kawakami H Ishihara et al. (2003) ArticleTitleImpact of aging on the development of hepatocellular carcinoma in patients with hepatitis C virus infection in Japan Scand J Gastroenterol 38 894–900 Occurrence Handle12940445 Occurrence Handle10.1080/00365520310004434 Occurrence Handle1:STN:280:DC%2BD3svgtFOiuw%3D%3D
K Kiyosawa T Umemura T Ichijo A Matsumoto K Yoshizawa A Gad et al. (2004) ArticleTitleHepatocellular carcinoma: recent trends in Japan Gastroenterology 127 IssueID5 Suppl 1 S17–26 Occurrence Handle15508082 Occurrence Handle10.1053/j.gastro.2004.09.012
MA Buendia (1998) ArticleTitleHepatitis B viruses and cancerogenesis Biomed Pharmacother 52 34–43 Occurrence Handle9755793 Occurrence Handle10.1016/S0753-3322(97)86239-7 Occurrence Handle1:STN:280:DyaK1cvivVGnsA%3D%3D
WS Robinson (1994) ArticleTitleMolecular events in the pathogenesis of hepadnavirus-associated hepatocellular carcinoma Annu Rev Med 45 297–323 Occurrence Handle8198385 Occurrence Handle10.1146/annurev.med.45.1.297 Occurrence Handle1:CAS:528:DyaK2cXktlajsLk%3D
T Someya K Ikeda S Saitoh M Kobayashi T Hosaka H Sezaki et al. (2006) ArticleTitleInterferon lowers tumor recurrence rate after surgical resection or ablation of hepatocellular carcinoma: a pilot study of patients with hepatitis B virus-related cirrhosis J Gastroenterol 41 1206–13 Occurrence Handle17287900 Occurrence Handle10.1007/s00535-006-1912-0 Occurrence Handle1:CAS:528:DC%2BD2sXhsV2isrg%3D
K Falasca C Ucciferri M Dalessandro P Zingariello P Mancino C Petrarca et al. (2006) ArticleTitleCytokine patterns correlate with liver damage in patients with chronic hepatitis B and C Ann Clin Lab Sci 36 144–50 Occurrence Handle16682509 Occurrence Handle1:CAS:528:DC%2BD28XlvVSlsrs%3D
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Uka, K., Aikata, H., Takaki, S. et al. Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. J Gastroenterol 42, 845–853 (2007). https://doi.org/10.1007/s00535-007-2099-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00535-007-2099-8